1. Home
  2. GDV vs HRMY Comparison

GDV vs HRMY Comparison

Compare GDV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Dividend & Income Trust of Beneficial Interest

GDV

Gabelli Dividend & Income Trust of Beneficial Interest

SELL

Current Price

$28.34

Market Cap

2.7B

Sector

Finance

ML Signal

SELL

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$37.45

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDV
HRMY
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GDV
HRMY
Price
$28.34
$37.45
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
★ $48.25
AVG Volume (30 Days)
78.4K
★ 750.6K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
★ 5.81%
N/A
EPS Growth
N/A
★ 7.97
EPS
N/A
★ 1.84
Revenue
N/A
★ $868,453,000.00
Revenue This Year
N/A
$18.62
Revenue Next Year
N/A
$13.23
P/E Ratio
★ N/A
$20.62
Revenue Growth
N/A
★ 21.51
52 Week Low
$26.14
$25.81
52 Week High
$31.00
$43.49

Technical Indicators

Market Signals
Indicator
GDV
HRMY
Relative Strength Index (RSI) 38.76 38.90
Support Level $28.07 $37.48
Resistance Level $29.51 $39.35
Average True Range (ATR) 0.30 1.25
MACD 0.04 -0.25
Stochastic Oscillator 48.98 35.36

Price Performance

Historical Comparison
GDV
HRMY

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: